TAK - Arrowhead Pharmaceuticals: Hoping Something Sticks
2024-05-27 10:05:29 ET
Summary
- Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook.
- The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemia indications.
- Arrowhead has collaborations potentially worth $2.8 billion and data from plozasiran due in 3Q24, which could set the tone for the stock for the rest of the year.
- A full analysis around Arrowhead Pharmaceuticals stock follows in the paragraphs below.
Shares of RNA interference concern Arrowhead Pharmaceuticals, Inc. ( ARWR ) are off more than 70% from their June 2021 high as the market worries about its near- to intermediate-term outlook. Its lead therapy and likely first-ever approved asset plozasiran is behind Ionis Pharmaceuticals' ( IONS ) olezarsen for its two hypertriglyceridemia indications. With collaboration milestones potentially worth $2.8 billion and data due from plozasiran in 3Q24 likely to set the tone for the balance of the year, Arrowhead merited a deeper dive. An analysis follows below....
Arrowhead Pharmaceuticals: Hoping Something Sticks